{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Evaluation+of+Escalating+Doses&page=4",
    "query": {
      "condition": "Safety Evaluation of Escalating Doses",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 147,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Evaluation+of+Escalating+Doses&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Evaluation+of+Escalating+Doses&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T01:49:49.680Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05496738",
      "title": "A Preliminary Study to Evaluate PF-07264660 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-07264660 intravenous single ascending dose",
          "type": "DRUG"
        },
        {
          "name": "PF-07264660 subcutaneous multiple ascending dose",
          "type": "DRUG"
        },
        {
          "name": "Intravenous placebo",
          "type": "OTHER"
        },
        {
          "name": "subcutaneous placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 59,
      "start_date": "2022-08-16",
      "completion_date": "2024-05-06",
      "has_results": false,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-10-10T01:49:49.680Z",
      "location_count": 6,
      "location_summary": "Garden Grove, California • Long Beach, California • Los Alamitos, California + 3 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05496738"
    },
    {
      "nct_id": "NCT00054977",
      "title": "Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Lung Cancer",
        "Breast Cancer",
        "Head and Neck Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GM-CT-01",
          "type": "DRUG"
        },
        {
          "name": "5-fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galectin Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2003-02",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2012-03-12",
      "last_synced_at": "2026-10-10T01:49:49.680Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00054977"
    },
    {
      "nct_id": "NCT03157167",
      "title": "An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kaposi Sarcoma",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Tc99m-tilmanocept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Navidea Biopharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2017-12-01",
      "completion_date": "2020-03-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-05",
      "last_synced_at": "2026-10-10T01:49:49.680Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03157167"
    },
    {
      "nct_id": "NCT00195312",
      "title": "Study Evaluating Vaccine in Adults With HIV",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "HIV-1 gag DNA (formulated with bupivacaine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-15 DNA (formulated with bupivacaine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-12 DNA (formulated with bupivacaine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride injection USP (0.9%)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 91,
      "start_date": "2005-08",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2007-12-05",
      "last_synced_at": "2026-10-10T01:49:49.680Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00195312"
    },
    {
      "nct_id": "NCT06067802",
      "title": "Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Medium-chain Acyl-CoA Dehydrogenase Deficiency"
      ],
      "interventions": [
        {
          "name": "Triheptanoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jerry Vockley, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2026-08",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-10T01:49:49.680Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06067802"
    },
    {
      "nct_id": "NCT02743871",
      "title": "Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Chronic Rhinosinusitis With Nasal Polyps",
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "PF-06817024",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for PF-06817024",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 97,
      "start_date": "2016-04-27",
      "completion_date": "2021-03-09",
      "has_results": true,
      "last_update_posted_date": "2022-05-19",
      "last_synced_at": "2026-10-10T01:49:49.680Z",
      "location_count": 20,
      "location_summary": "Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Shelton",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02743871"
    },
    {
      "nct_id": "NCT00511368",
      "title": "Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Bevirimat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myrexis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 92,
      "start_date": "2006-04",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2010-01-20",
      "last_synced_at": "2026-10-10T01:49:49.680Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00511368"
    },
    {
      "nct_id": "NCT02047604",
      "title": "(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "SAN-300 0.5 mg/kg QW",
          "type": "DRUG"
        },
        {
          "name": "SAN-300 1.0 mg/kg QW",
          "type": "DRUG"
        },
        {
          "name": "SAN-300 2.0 mg/kg QOW",
          "type": "DRUG"
        },
        {
          "name": "SAN-300 4.0 mg/kg QOW",
          "type": "DRUG"
        },
        {
          "name": "SAN-300 4.0 mg/kg QW",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 41,
      "start_date": "2013-12",
      "completion_date": "2017-03-23",
      "has_results": true,
      "last_update_posted_date": "2021-06-21",
      "last_synced_at": "2026-10-10T01:49:49.680Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • El Cajon, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Leandro",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02047604"
    },
    {
      "nct_id": "NCT01485146",
      "title": "A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety Evaluation of Escalating Doses"
      ],
      "interventions": [
        {
          "name": "ETC-1002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Esperion Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-10-25",
      "completion_date": "2012-01-25",
      "has_results": false,
      "last_update_posted_date": "2019-03-28",
      "last_synced_at": "2026-10-10T01:49:49.680Z",
      "location_count": 1,
      "location_summary": "Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01485146"
    },
    {
      "nct_id": "NCT02445963",
      "title": "Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Shigellosis",
        "Bacillary Dysentery"
      ],
      "interventions": [
        {
          "name": "Shigella flexneri 2a InvaplexAR",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 38,
      "start_date": "2015-10-01",
      "completion_date": "2016-05-13",
      "has_results": true,
      "last_update_posted_date": "2021-02-12",
      "last_synced_at": "2026-10-10T01:49:49.680Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02445963"
    }
  ]
}